Next 10 |
home / stock / esalf / esalf news
2024-04-24 08:03:47 ET More on Biogen Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Bio...
2024-04-22 00:58:35 ET Summary The FDA has convened an advisory panel to discuss the safety and efficacy of Eli Lilly's anti-amyloid antibody drug donanemab. Approval of donanemab could have a modestly positive impact on LLY stock, while denial could lead to a substantial (but not...
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...
2024-04-16 15:31:20 ET More on Biogen, Eisai, etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) GLP-1s benefit Parkinson’...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the ...
2024-04-01 06:04:15 ET More on Biogen, Eisai Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) EU delays decision on Eisai-Biogen Alz...
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA TOKYO and CAMBRIDGE, Mass., Apr 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. annou...
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name:...
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the ...